AcouSort selected by EIC for participation at MEDICA, Europe´s leading medical exhibition
AcouSort has been selected by the European Innovation Council (EIC) for participation at MEDICA 2022 after a highly competitive evaluation process. AcouSort is thus one of the 20 companies selected by EU for full sponsorship at Europe’s leading medical exhibition, taking place in Düsseldorf November 14-17.
“It is of course incredibly inspiring, for the second time this year, to be selected for full sponsorship by the EIC. In June, we participated in the European Pavilion at BIO2022 in San Diego, and in November we will participate at MEDICA, which is one of the most important exhibitions in the healthcare industry,” says AcouSort’s CEO Torsten Freltoft.
During the exhibition, AcouSort will mainly focus on partnering and 1-on-1 meetings, discussing future OEM solutions within both point-of-care diagnostics and personalized medicine such as novel cancer therapies.
MEDICA is the world’s largest event for the medical sector. The exhibition attracts several thousand exhibitors from more than 50 countries, alongside tens of thousands of national and international experts and decision-makers.
In parallel with MEDICA, AcouSort will also attend the exhibition COMPAMED 2022, which is also held in Düsseldorf at the same time as MEDICA. COMPAMED is an important exhibition for companies that sell OEM components. The exhibition is thereby an excellent opportunity for AcouSort to display its OEM components to a broader audience working with designing the next gen diagnostic and therapeutic devices.
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
About AcouSort
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank, 08-463 83 00, mail to: certifiedadviser@penser.se Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.